A <scp>P</scp> hase <scp>IIb</scp> , randomized, placebo‐controlled study of the <scp>SGLT2</scp> inhibitor empagliflozin in patients with type 2 diabetes

Abstract

In patients with type 2 diabetes, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo. Empagliflozin was well-tolerated with a favourable safety profile.